Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Östör

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Expert Opinion on Drug Safety|January 3, 2015
Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritisMaeve McLaughlin, Andrew Östör
Expert Opinion on Emerging Drugs|September 14, 2022
Emerging injectable therapies for osteoarthritisJulia Sewell, Andrew Östör
Arthritis Care & Research|August 2, 2024
Barriers to, Facilitators of, and Interventions to Support Treat-to-Target Implementation in Rheumatoid Arthritis: A Systematic ReviewLaure Gossec, Louis Bessette, Ricardo M Xavier, et al.
Journal of Market Access & Health Policy|July 26, 2017
Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European regionZoltán Kaló, Zoltán Vokó, Andrew Östör, et al.
Arthritis Research & Therapy|June 13, 2025
Association between rapid and sustained remission and clinician- and patient-reported outcomes in patients with rheumatoid arthritis: post hoc analysis of data from the SELECT-COMPARE studyLaure Gossec, Jayesh Patel, Aditi Kadakia, et al.
Rheumatology and Therapy|December 23, 2025
Long-Term Effectiveness of Baricitinib and Other b/tsDMARDs in Patients with Rheumatoid Arthritis with Early Low Disease Activity or Remission: 2-Year Data from the RA-BE-REAL StudyRieke Alten, Andrew Östör, Christopher J Edwards, et al.
Rheumatology and Therapy|February 23, 2023
Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing SpondylitisVictoria Navarro-Compán, Xenofon Baraliakos, Marina Magrey, et al.
Arthritis Research & Therapy|April 11, 2025
Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational studyAndrew Östör, Eugen Feist, Prodromos Sidiropoulos, et al.
Rheumatology (Oxford, England)|October 25, 2022
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 studyAndrew Östör, Filip Van den Bosch, Kim Papp, et al.
Rheumatology and Therapy|September 27, 2023
Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European PatientsRieke Alten, Gerd R Burmester, Marco Matucci-Cerinic, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Expert Opinion on Drug Safety|January 3, 2015
Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritisMaeve McLaughlin, Andrew Östör
Expert Opinion on Emerging Drugs|September 14, 2022
Emerging injectable therapies for osteoarthritisJulia Sewell, Andrew Östör
Arthritis Care & Research|August 2, 2024
Barriers to, Facilitators of, and Interventions to Support Treat-to-Target Implementation in Rheumatoid Arthritis: A Systematic ReviewLaure Gossec, Louis Bessette, Ricardo M Xavier, et al.
Journal of Market Access & Health Policy|July 26, 2017
Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European regionZoltán Kaló, Zoltán Vokó, Andrew Östör, et al.
Arthritis Research & Therapy|June 13, 2025
Association between rapid and sustained remission and clinician- and patient-reported outcomes in patients with rheumatoid arthritis: post hoc analysis of data from the SELECT-COMPARE studyLaure Gossec, Jayesh Patel, Aditi Kadakia, et al.
Rheumatology and Therapy|December 23, 2025
Long-Term Effectiveness of Baricitinib and Other b/tsDMARDs in Patients with Rheumatoid Arthritis with Early Low Disease Activity or Remission: 2-Year Data from the RA-BE-REAL StudyRieke Alten, Andrew Östör, Christopher J Edwards, et al.
Rheumatology and Therapy|February 23, 2023
Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing SpondylitisVictoria Navarro-Compán, Xenofon Baraliakos, Marina Magrey, et al.
Arthritis Research & Therapy|April 11, 2025
Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational studyAndrew Östör, Eugen Feist, Prodromos Sidiropoulos, et al.
Rheumatology (Oxford, England)|October 25, 2022
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 studyAndrew Östör, Filip Van den Bosch, Kim Papp, et al.
Rheumatology and Therapy|September 27, 2023
Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European PatientsRieke Alten, Gerd R Burmester, Marco Matucci-Cerinic, et al.
Pageof 2